Microcap Ledger TScan Therapeutics, Inc. $TCRX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Waltham, MA
- Fiscal year end
- December 31
What the company doesAI summary of filing
TScan Therapeutics is a clinical-stage biopharmaceutical company developing TCR-T cell therapies for cancer and blood disorders. The company engineers T cells to express tumor-specific T cell receptors and manufactures these therapies through complex processes involving transposons and transposase insertion into patient T cell genomes. TScan generates no revenue and is focused on advancing product candidates through clinical trials, with manufacturing conducted through internal facilities and third-party manufacturers. The company faces significant regulatory, manufacturing, and commercialization risks typical of early-stage cell therapy developers seeking FDA approval. [10-K 2026-03-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $2.03M | −$59.02M | −$51.81M | $100.16M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $10.32M | −$129.77M | −$135.32M | $152.41M | [10-K 2026-03-04] |
| FY ended Dec 2024 | $2.82M | −$127.50M | −$110.82M | $178.69M | [10-K 2026-03-04] |
- Quarterly cash burn
- −$25.91M
- Cash runway Estimate
- ~11.6 months
Capital structure and dilution
- Shelf registration
- S-3 filed 2025-03-05; declared effective 2025-03-14 [S-3 2025-03-05]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-09-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-09-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-09-02] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Macbeath Gavin | grant | 1,000,000 | — | [4 2026-10-02] |
| 2026-10-01 | Zdraveski Zoran | grant | 300,000 | — | [4 2026-10-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-30 | 8-K | Director or officer change |
| 2026-09-25 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-11 | 8-K | Director or officer change |
| 2026-09-02 | 8-K | Exit or disposal costs; Listing notice or transfer; Director or officer change |
| 2026-08-18 | 8-K | Material agreement terminated |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Results of operations |
| 2026-06-22 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-22 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $TCRX
Email me when TScan Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.